HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICCVAM’s LLNA report available

This article was originally published in The Rose Sheet

Executive Summary

11Report from scientific panel convened in late April by the International Coordinating Committee on the Validation of Alternative Methods to review murine local lymph node assay test is now available at the NICEATM/ICCVAM Web site; public comment is invited. LLNA test is used to determine if substances may cause allergic contact dermatitis. Panel greenlighted two nonradioactive versions of the LLNA, with certain limitations, and showed support for third method "contingent upon demonstration of adequate interlaboratory reproducibility ... and an audit to verify summary data submitted for review" (2"The Rose Sheet" May 18, 2009, In Brief). ICCVAM will consider report and public feedback before making recommendation to federal agencies, which could lead to further reduction of animal use in product safety testing. ICCVAM panel met May 19-21 to consider alternative methods for gauging the eye irritation potential of antimicrobial cleaning products and determined data insufficient to support the EpiOcular, Cytosensor Microphysiometer and bovine corneal opacity and permeability assays (3"The Rose Sheet" June 1, 2009, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel